MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why TELA Stock dropped -5.74% Today — RQD Quant Desk Flash
$0.92 -5.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.91
TELA Bio Inc. (TELA) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $41.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.91 (-1.22%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TELA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY TELA SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 67.7% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+9/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.11-11.7% Next Q
44
Q2 (-2Q)Grade D$0.98-2% Next Q
41
Q3 (-1Q)Grade E$0.96-4.2% Next Q
39
CurrentGrade D-$0.92-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TELA Turnaround Squeeze
While TELA currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.01) and Max Pain ($0.97) forces dealer call-delta covering toward $1.58.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TELA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TELA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TELA Stock dropped -5.74% Today — RQD Quant Desk Flash
TELA Bio Inc. (TELA) dropped -5.74% to $0.92, trading at 42% of its 52-week range ($0.5 – $1.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 42% of its 52-week range ($0.5 – $1.5) with RSI-14 at 33.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.92 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 67.7% gross margin and $0 annual free cash flow.
Live TELA Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TELA)
- ✓Walkthrough of TELA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TELA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.55%📐 HORIZONTAL RANGE
2026-10-30O $0.91H $0.92L $0.81C $0.92VOL 330.1K
RES: $1.68SUP: $0.50SMA50: $1.01SMA200: $0.86
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TELA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +15.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TELA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TELA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TELA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TELA)
Health Care Rank #791 of 1016
⚔️ XTNT vs TELA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TELA vs. XTNT, SNWV, CVRX, SRTS)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, TELA Bio Inc. (TELA) ranks #791 by composite RQD confidence (36/100, grade D-) and #771 by equity capitalization ($41.5M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with TELA at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TELA
ACTIVE
TELA Bio Inc. | D- | 36/100 | — | 67.7% | -35.0% | -5.74% | $41.5M | Benchmark Subject |
| XTNT Xtant Medical Holdings Inc. | C+ | 69/100 | — | 62.9% | 12.8% | +1.54% | $40.7M | /xtnt-vs-tela → |
| SNWV SANUWAVE Health Inc. | D+ | 53/100 | 3.8x | 77.1% | 67.3% | 0.00% | $45.3M | /snwv-vs-tela → |
| CVRX CVRx Inc. | D- | 43/100 | — | 85.3% | -35.0% | +1.79% | $38.0M | /cvrx-vs-tela → |
| SRTS Sensus Healthcare Inc. | D | 46/100 | — | 43.2% | -31.3% | -1.77% | $45.6M | /srts-vs-tela → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001561921In its most recent audited fiscal period (FY2025, filed 2025-12-31), TELA Bio Inc. (TELA) reported GAAP revenue of $80.3M (+15.8% vs. FY2024 revenue of $69.3M , and +37.3% cumulative change since FY2023) , GAAP net income of -$38.8M, operating cash flow of -$28.2M, and free cash flow of -$28.7M (+32.7% YoY). On the balance sheet, TELA closed FY2025 with $81.4M in total assets against $55.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $80.3M | -$38.8M | -$28.2M | -$28.7M | $81.4M | $55.7M |
| FY2024 (FY) | 2024-12-31 | $69.3M | -$37.8M | -$41.6M | -$42.6M | $86.6M | $41.1M |
| FY2023 (FY) | 2023-12-31 | $58.5M | -$46.7M | -$40.9M | -$40.9M | — | — |
3. TELA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TELA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, TELA Bio Inc. (NASDAQ: TELA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.92 (-5.74% 1D, market cap $41.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TELA ranks #791 in composite RQD confidence.
How does TELA compare to XTNT and SNWV in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), TELA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of -35.0%. By comparison, XTNT (Xtant Medical Holdings Inc.) holds a C+ grade (69/100 RQD, P/E N/A, ROIC 12.8%, cap $40.7M) and SNWV (SANUWAVE Health Inc.) posts a D+ grade (53/100 RQD, P/E 3.8x, ROIC 67.3%, cap $45.3M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TELA?
Per TELA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001561921), TELA Bio Inc. generated $80.3M in revenue (+15.8% YoY), -$38.8M in net income, and -$28.7M in free cash flow against $81.4M in total assets and $55.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TELA trading relative to its 50-day, 200-day, and 52-week technical levels?
TELA last traded at $0.92 (-5.74% on volume of 49,274 shares), positioning the stock -8.91% below its 50-day simple moving average ($1.01) and +6.98% above its 200-day simple moving average ($0.86). Across its 52-week range of $0.50 to $1.50, TELA sits at the 42.0% percentile with a 14-day RSI of 33.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.04).
TELA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TELA stock moving today?
Why TELA Stock dropped -5.74% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.